Rocket Pharmaceuticals (RCKT) announced that the FDA has accepted the resubmission of the biologics license application for Kresladi, a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I, a rare genetic immune disorder that predisposes patients to recurrent and fatal infections and is near-uniformly fatal in childhood without an allogeneic hematopoietic stem cell transplant. The PDUFA date set by the FDA is March 28, 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Strategic Shift Towards Cardiovascular Platform Positions Rocket Pharmaceuticals for Future Growth
- Rocket Pharmaceuticals Board Member Resigns in September
- No jobs report amid shutdown, Apple pulls ICEBlock from App Store: Morning Buzz
- Rocket Pharmaceuticals price target lowered to $7 from $9 at Leerink
- Hold Rating on Rocket Pharmaceuticals Amid Strategic Shifts and Regulatory Challenges